ADGRA2 and hematocrit: Further analysis showed that 23.1% PH patients carried GPR124 c.3587G>A mutation compared to only 6.8% carriers in non‐PH patients (Figure 2A), suggesting a potential role of this point mutation in the pathogenesis of HT in at least a subset of AIS patients.